DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05324462

SPIRIT

Completed

Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia

Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia - A Single-arm, Non-interventional Retrospective Chart Review Study

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

6

Recruiting sites

—

Enrollment

175

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05324462
Org study IDNN9068-4884
Secondary IDU1111-1266-5484World Health Organization (WHO)

Timeline

Milestones

Study start2022-03-22actual
Study first posted2022-04-12actual
Primary completion2022-07-15actual
Study completion2022-07-15actual
Last update posted2022-11-09actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

The study population will consist of male or female adults (above or equal to 18 years at the time of data collection) who are diagnosed with T2D for at least 12 months prior to data collection and were previously treated with basal insulin plus/minus OADs prior to initiating IDegLira. The HbA1c measurement below or equal to 12 weeks prior to IDegLira initiation should be available and documented for each patient to be eligible in the study

Inclusion criteria

1. Male or female, age above or equal to 18 years at the time of data collection.

2. Patient diagnosed with T2D greater than or equal to 12 months prior to data collection.

3. The decision to initiate treatment with commercially available IDegLira has been made by the patient and the treating physician before, which is independent from the decision to participate in this study.

4. Treated with basal insulin plus/minus OADs prior to initiating IDegLira.

5. Available and documented HbA1c measurement below or equal to 12 weeks prior to IDegLira initiation.

Exclusion criteria

1. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

2. Diagnosed with type 1 diabetes mellitus, maturity-onset diabetes of the young, latent autoimmune diabetes in adults, gestational diabetes or any hyperglycaemic state other than T2D.

3. Women known to be pregnant or breastfeeding during the conduct of the study.

4. Patients with basal-bolus insulin prior to IDegLira initiation.

5. Participation in another T2D clinical study that involves any clinical intervention or administration of an investigational drug within 3 months prior to initiating IDegLira.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
1
Glycemic / diabetes
1
Other (unclassified)
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Change in absolute body weight

Time frame:From baseline (week 0) to end of study (week 26 plus/minus 6 weeks) after IDegLira initiation

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Primary/protocol endpoint

Change in local laboratory measured Glycated Haemoglobin A1c (HbA1c)

Time frame:From baseline (week 0) to end of study (week 26 plus/minus 6 weeks) after IDegLira initiation

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Comparison between the daily dose of basal insulin and IDegLira

Time frame:From baseline (week 0) to end of study (week 26 plus/minus 6 weeks) after IDegLira initiation

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.